Impact of Probiotics on the Prevention and Treatment of Gastrointestinal Diseases in the Pediatric Population

Int J Mol Sci. 2023 May 29;24(11):9427. doi: 10.3390/ijms24119427.

Abstract

Despite the high prevalence of gastrointestinal disorders (GIDs) in infants and children, especially those categorized as functional GIDs (FGIDs), insufficient knowledge about their pathophysiology has limited both symptomatic diagnosis and the development of optimal therapies. Recent advances in the field of probiotics have made their potential use as an interesting therapeutic and preventive strategy against these disorders possible, but further efforts are still needed. In fact, there is great controversy surrounding this topic, generated by the high variety of potential probiotics strains with plausible therapeutic utility, the lack of consensus in their use as well as the few comparative studies available on probiotics that record their efficacy. Taking into account these limitations, and in the absence of clear guidelines about the dose and timeframe for successful probiotic therapy, our review aimed to evaluate current studies on potential use of probiotics for the prevention and treatment of the most common FGIDs and GIDs in the pediatric population. Furthermore, matters referring to know major action pathways and key safety recommendations for probiotic administration proposed by major pediatric health agencies shall also be discussed.

Keywords: children; functional gastrointestinal disorders; gastrointestinal disorders; gut microbiota; infants; probiotics.

Publication types

  • Review

MeSH terms

  • Child
  • Consensus
  • Gastrointestinal Diseases* / drug therapy
  • Gastrointestinal Diseases* / prevention & control
  • Humans
  • Infant
  • Probiotics* / therapeutic use

Grants and funding

José Antonio García-Santos was supported by a grant from the Ministry of Economic Transformation, Industry, Knowledge and University of the Junta de Andalucía (Andalusian Plan for Research, Development and Innovation, PAIDI 2020, Code 20804). Tomás Cerdó was supported by ‘Sara Borrell’ program (Code CD21/00187) from Spanish Institute of Health Carlos III (ISCIII).